A comparison of the estimated costs of erlotinib, docetaxel...

A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective

Kotowa, Wioletta, Gatzemeier, Ulrich, Pirk, Olaf, Gabriel, Anja, Heigener, David
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
10
Language:
english
Journal:
Journal of Medical Economics
DOI:
10.3111/13696990701438637
Date:
January, 2007
File:
PDF, 734 KB
english, 2007
Conversion to is in progress
Conversion to is failed